Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00027547
- Locations
- 🇺🇸
Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
🇩🇪Universitaet Leipzig, Leipzig, Germany
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 130
- Registration Number
- NCT00016419
- Locations
- 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
- Conditions
- Recurrent Adult Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Childhood Non-Hodgkin LymphomaRefractory Childhood Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hodgkin LymphomaRefractory Non-Hodgkin LymphomaT-Cell Chronic Lymphocytic LeukemiaT-Cell Prolymphocytic LeukemiaRecurrent Childhood Hodgkin Lymphoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell TransplantationDrug: CarmustineDrug: CyclophosphamideDrug: CyclosporineDrug: CytarabineDrug: EtoposideDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: MelphalanDrug: Mycophenolate MofetilProcedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Peripheral Blood Stem Cell TransplantationBiological: Therapeutic Autologous LymphocytesRadiation: Total-Body Irradiation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 76
- Registration Number
- NCT00005803
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸LDS Hospital, Salt Lake City, Utah, United States
🇺🇸VA Puget Sound Health Care System, Seattle, Washington, United States
Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- University of California, Davis
- Registration Number
- NCT00009763
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
- First Posted Date
- 2003-01-08
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT00051311
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
- Conditions
- Interventions
- First Posted Date
- 2002-12-18
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 20
- Registration Number
- NCT00050648
- Locations
- 🇺🇸
Rockefeller University Hospital, New York, New York, United States
🇺🇸Rockefeller University, New York, New York, United States
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2006-07-17
- Target Recruit Count
- 25
- Registration Number
- NCT00001533
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 30
- Registration Number
- NCT00001731
- Locations
- 🇺🇸
National Eye Institute (NEI), Bethesda, Maryland, United States
A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 182
- Registration Number
- NCT00001839
- Locations
- 🇺🇸
Warren G. Magnuson Clinical Center (CC), Bethesda, Maryland, United States
A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 539
- Registration Number
- NCT00048152
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.